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Abstract Inherited metabolic disorders are the cause of a
small but significant number of sudden unexpected deaths
in infancy. We report a girl who suddenly died at 11 months
of age, during an intercurrent illness. Autopsy showed
spongiform lesions in the subcortical white matter, in the
basal ganglia, and in the dentate nuclei. Investigations in an
older sister with developmental delay, ataxia, and tremor
revealed L-2-hydroxyglutaric aciduria and subcortical white
matter changes with hyperintensity of the basal ganglia and
dentate nuclei at brain magnetic resonance imaging. Both
children were homozygous for a splice site mutation in the
L2HGDH gene. Sudden death has not been reported in
association with L-2-hydroxyglutaric aciduria so far, but
since this inborn error of metabolism is potentially
treatable, early diagnosis may be important.
Keywords L-2-Hydroxyglutarate . Sudden death . SIDS .
SUDI . Organic aciduria
Introduction
L-2-Hydroxyglutaric aciduria (OMIM 236792) is an inborn
error of metabolism characterized by the accumulation of
L-2-hydroxyglutaric acid in body fluids [3, 13]. Since the
first description of L-2-hydroxyglutaric aciduria in 1980
[13], less than 100 cases have been reported [2, 4, 5, 6, 8–
11, 14–16, 18, 20, 21, 23, 26, 27, 29, 38, 41–45, 47, 48].
Common clinical features include developmental delay,
macrocephaly, ataxia, pyramidal signs, and seizures. The
clinical course is usually slowly progressive, without acute
phases of neurological deterioration. Brain magnetic reso-
nance imaging (MRI) shows bilateral involvement of the
pallidum, the dentate nuclei, and subcortical white matter
[1, 8, 28, 35–37]. Neuropathology descriptions mainly
report spongiosis of the subcortical white matter with cystic
cavitations [20, 35], diffuse astrocytosis predominating in
the cerebral and cerebellar white matter [5], gliosis, and
neuronal loss in the dentate nuclei [5, 35]. Interestingly,
brain tumors seem to occur with increased frequency in
L-2-hydroxyglutaric aciduria and represent a possible cause
of death [2, 19, 24, 45]; the mechanism of this unusual
phenomenon is unclear. A very severe form of L-2-
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hydroxyglutaric aciduria with neonatal death has been
reported by Chen and coauthors [5]. Otherwise, no sudden
infant death has been reported in L-2-hydroxyglutaric
aciduria so far, and this disorder is not listed among the
several inherited metabolic disorders associated with
sudden unexpected death in infancy (SUDI) [7, 25]. This
paper describes two siblings with L-2-hydroxyglutaric
aciduria, presenting with two drastically different clinical
courses, and reports the first instance of association of this
inborn error of metabolism with SUDI.
Case reports
Patient 1 was an 11-month-old girl, born to consanguineous
parents of Tamil origin. She was the third child after an
11-year-old healthy sister and a 9-year-old sister (patient 2).
The father suffers from type 1 diabetes; the family history is
otherwise unremarkable.
Pregnancy and delivery were uneventful. Growth and
psychomotor development were fully normal until age
10 months, when she presented, within 10 h, three episodes
of activity arrest and staring during a few minutes. Each
episode was followed by post-ictal sleep and full recovery.
She did not present any other sign of illness and had no
fever. Clinical examination, including neurological status
and fundoscopy, was perfectly normal between the epi-
sodes. Her weight was 10.6 kg (P90), length 75 cm (P50),
and fronto-occipital head circumference 47 cm (P90–97).
Routine blood, urine, and cerebrospinal fluid (CSF) inves-
tigations, as well as cardiac investigations and microbio-
logical screening were negative. Electroencephalography
(EEG) showed non-specific posterior slow waves without
epileptiform discharges. One week later, during an inter-
current febrile illness with diarrhea since 48 h, she suddenly
died while sleeping in her mother’s arm. The mother
reported no abnormal eye or limb movement and no
respiratory distress. She was examined a few hours earlier
at the pediatric hospital, and the clinical examination did
not show any sign of severe infection; there was no
dehydration and no neurological abnormality.
Pathology A complete autopsy was performed in accor-
dance to national regulations for unexpected death. Samples
from every organ were collected after dissection, fixed in
formalin, and stained with hematoxylin–eosin. Complete
body X-ray, samples from blood, vitreous, muscle, and
gastric content were submitted for toxicologic tests as well
as bacteriology and virology cultures from blood, lungs,
and liver tissues; all these tests resulted to be normal. The
autopsy revealed that all organs were normal in size and
structure. There was no evidence of trauma, malformation,
malignancy, or infection. Brain weight was 1,032 g, slightly
higher than expected for age (normal range, 900–950 g).
On visual inspection of the central nervous system, the
cerebral conformation was normal, and no herniation was
seen. On coronal sections, the ventricular system was not
enlarged, and there was normal appearance of the gray and
white matter. On histology, there was bilateral striking
vacuolation in the subcortical white matter (Figs. 1a,b),
around and within the putamen, in the dentate nuclei and
surrounding in the cerebellum (Fig. 1c). The cerebellar folia
were unremarkable. In all involved areas, the spongiosis
was accompanied by significant astrogliosis. The vacuoles
were mainly seen in the myelin sheaths (Fig. 1d). There
was no evidence of neuronal loss, no axonal damage, and
no significant vascular changes.
Molecular investigations Genomic DNAwas extracted from
a frozen muscle specimen, collected during autopsy. Molec-
ular analysis in the L2HGDH gene was performed after the
diagnosis was made in patient 2, and revealed the homozy-
gous splice site mutation c.738+1G>A (IVS6+1G>A); both
parents were carriers of this mutation.
Patient 2 is the 9-year-old sister of patient 1. She was
born at term after an uneventful pregnancy and delivery.
Psychomotor development was slightly delayed in the first
years of life, with walking at 18 months and language
delay. At age 3 and 4 years, she presented two episodes of
uncomplicated generalized febrile convulsions. She was
seen for the first time at the age of 6 years: She presented
with nonspecific global developmental delay with motor
clumsiness, without pyramidal signs. From age 6 to 9 years,
she progressively developed action tremor, light gait ataxia,
dysarthria and drooling, and moderate mental retardation.
No neurological deterioration was reported during febrile
illness. Several attempts to obtain brain imaging failed, and
further investigations were not possible because of lack of
compliance.
One month after the death of her younger sister, during a
viral infection, she presented a unique episode of activity
arrest with hypotonia and upward eye deviation, followed
by post-ictal sleep. Neurological examination showed gait
ataxia with clear imbalance at cerebellar testing, action and
intention tremor, and dysarthria. Cranial nerves and deep
tendon reflexes were normal. Fundoscopy did not show any
papillary edema. Her weight was 33 kg (P75), height
136 cm (P50–75), and fronto-occipital head circumference
53.8 cm (P90–97). The clinical examination was otherwise
normal. EEG revealed nonspecific excess of slow waves at
the vertex without epileptiform discharges.
Neuroradiological investigation Brain MRI at the age of
9 years showed predominantly frontal subcortical white
matter hyperintensity on T2 sequences, with abnormal
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signal in bilateral dentate nuclei and slight signal alteration
in the basal ganglia (Fig. 2). Standard multivoxel and
monovoxel proton spectroscopy was normal.
Biochemical and molecular investigations Routine blood,
urine, and CSF analysis were normal. Acylcarnitines
profile was normal, as well as carbohydrate-deficient
glycoprotein analysis. Urinary organic acids analysis in
multiple urine samples revealed markedly increased
excretion of 2-hydroxyglutarate (1612–2477 mmol/mol
creatinine; normal range <15.4). Enantiomeric separation
[40] confirmed that most of the excreted 2-hydroxyglutarate
was in its L-form (L-2-hydroxyglutarate 1,580 mmol/mol
creatinine), whereas D-2-hydroxyglutarate excretion was
within the control range. Plasma amino acids showed
increased lysine levels (359 μmol/l; normal range,
116–250). CSF analysis showed markedly increased 2-
hydroxyglutarate (51 μmol/l; normal range, <3) and lysine
(72 μmol/l; normal range, 15–37). Genomic DNA was
extracted from peripheral blood and molecular analysis in
the L2HGDH gene revealed the same homozygous splice
site mutation found in patient 1 (IVS6+1G>A).
Treatment Therapeutic trials were performed with oral coen-
zyme Q10 (400 mg/day) during 6 months and, more recently,
with oral riboflavin (200 mg/day) during 2 months. L-2-
Hydroxyglutarate in urine and lysine in plasma were
monitored every 4 weeks during both trials, and no
significant reduction was observed. CSF L-2-hydroxyglutarate
was measured in CSF before and during treatment, without
any significant change. Brain MRI findings remained
unchanged before and after the trial with coenzyme Q10.
Clinical neurological assessment was unchanged before,
during, and after the trials with both substances.
Discussion
While the clinical presentation of patient 2 with early-onset
delay of psychomotor milestones, ataxia, tremor, and
slowly progressive clinical course is similar to the majority
of the reported cases, her sibling had normal psychomotor
development until sudden unexpected death at 11 months,
during a mild intercurrent illness. Neuropathology findings of
patient 1 corresponded well to the neuroradiological changes
of patient 2, despite very different clinical courses. Current
knowledge on the molecular bases of L-2-hydroxyglutaric
aciduria shows no clear correlation between genotype and
phenotype [34] and no correlation between neuroradiological
images, severity of the disease, and prognosis. The family
presented in this paper, the first reported of Tamil origin,
segregates a previously undescribed mutation in the univer-
sally conserved GT dinucleotide at a donor splice site in the
L2HGDH gene that is predicted to affect splicing like in two
other reported patients [43]. Our report confirms intrafamilial
phenotypic variability despite identical genotypes and lack
of correlation between the extent of brain lesions and clinical
signs and symptoms.
Clinical heterogeneity in affected siblings is known in
L-2-hydroxyglutaric aciduria [9, 15], but sudden death has
Fig. 1 Brain histopathology of
patient 1: a section of cerebral
cortex and white matter showing
subcortical spongiosis (arrow)
and vascular congestion. No
significant myelin loss. HE-LFB
20×. Insert Immunohistochemis-
try with glial fibrillary acidic
protein (GFAP) revealing strong
positive reaction of astrogliosis at
the subcortical level. GFAP 20×.
b Higher power level showing
the numerous vacuoles (arrow) in
the subcortical matter. HE 200×.
c Section of cerebellum with
marked spongiosis (arrow) within
the dentate nucleus, no abnor-
mality within the cerebellar folia.
HE-LFB 40×. d High power of
cerebellar white matter near the
dentate nucleus showing marked
vacuolation (arrow) within the
myelin sheaths. HE-LFB 400×.
Insert Immunohistochemistry
with GFAP revealing the signifi-
cant astrogliosis surrounding the
vacuolated white matter
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not been previously described in this disorder. This
unexpected observation raises questions concerning the
primary pathogenetic process. L-2-Hydroxyglutaric aciduria
is caused by deficient activity of the flavin adenine
dinucleotide (FAD)-dependent enzyme L-2-hydroxyglutaric
dehydrogenase, which converts L-2-hydroxyglutarate to
alpha-ketoglutarate [30, 31]. It has been proposed that
L-2-hydroxyglutaric aciduria is a “metabolite repair” disorder
[32], in which L-2-hydroxyglutarate, a byproduct of the
Krebs cycle, fails to be re-converted in its own precursor
(alpha-ketoglutarate). Both the toxic effect of accumulated
L-2-hydroxyglutarate [39] and alpha-ketoglutarate depletion
[17] are currently considered as possible pathogenetic
mechanisms. Reduced availability of alpha-ketoglutarate for
the Krebs cycle may cause a major derangement in energy
metabolism, which seems to be the common pathogenetic
mechanism of organic acidurias known to be associated to
SUDI, although the final molecular mechanism triggering
sudden death remains unknown.
To date, only one case of infant death associated with
L-2-hydroxyglutaric aciduria has been reported [5]; however,
the patient was critically ill, and the early death was not
unexpected, as there was severe neonatal encephalopathy
and rapid deterioration at 1 month of age. Three other cases
of death in childhood were attributed to development of
cerebral tumors [2, 24, 45]. This is the first report of
unexpected death without pre-existing clinical signs in a
child with L-2-hydroxyglutaric aciduria. Autopsy findings
give no argument for overwhelming infectious disease,
although it cannot formally be excluded. Pathology studies
exclude the presence of brain tumor and the involvement of
any other organ as the ultimate cause of death. Brain
histopathological abnormalities are similar to the previously
reported cases [5, 20, 35] and do not allow to point at a
specific brain lesion as the cause of death. In contrast to the
other reported cases of infancy/childhood death in L-2-
hydroxyglutaric aciduria, our patient’s clinical presentation
is that of a SUDI, in terms of age, death occurring during
sleep, and concomitant associated diagnosis of a metabolic
disorder [7]. However, until further cases are reported, it
cannot be determined whether this association is causative
or coincidental. Inborn errors of metabolism have been
diagnosed in 2% to 5% of SUDI [12] but may remain
underdiagnosed in centres lacking expertise in pediatric
pathology and metabolic investigation protocols [22]. The
importance of a protocol for the laboratory investigation of
SUDI has been highlighted by Olpin and coauthors [25];
however, post-mortem diagnosis of an inborn error of
metabolism is often difficult due to the sensitivity of
biochemical analysis in body fluids or tissues to proteolytic
deterioration of inner organs. When urine and/or CSF are
available, organic acid analysis by gas chromatography
mass spectrometry is the best test to diagnose L-2-
hydroxyglutaric aciduria. Although rare, the diagnosis of a
metabolic disorder in SUDI allows not only appropriate
genetic and reproductive counseling but also the detection
of affected siblings and, for some disorders, appropriate
treatment.
Until recently, there was no effective specific therapy for
L-2-hydroxyglutaric aciduria. Two very recent reports
indicate the possible therapeutic role of FAD [33], cofactor
of the enzyme, and of its precursor riboflavin [46]. We
could not confirm this observation in patient 2. However, if
the spectacular clinical improvement of L-2-hydroxyglutaric
aciduria patients under riboflavin/FAD treatment observed
in these first reports will be confirmed in further cases,
Fig. 2 Brain MRI of patient 2 at
age 9 years: a hyperintensity of
the subcortical white matter
(upper arrows) and dentate
nuclei (lower arrow) in T2
ponderation; b slight signal
alteration of the basal ganglia
(arrow) in T2 ponderation
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early identification of this inborn error of metabolism in
affected families may result in a better neurological
prognosis and possibly in prevention of SUDI.
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